VYGR (Voyager Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by VYGR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-11 | JAMES A GERAGHTY | Director | A | — | — |
| 2026-06-11 | Jude Onyia | Director | A | — | — |
| 2026-06-11 | CATHERINE J MACKEY | Director | A | — | — |
| 2026-06-11 | Michael J Higgins | Director | A | — | — |
| 2026-06-11 | Nancy Vitale | Director | A | — | — |
| 2026-06-11 | GLENN PIERCE | Director | A | — | — |
| 2026-06-11 | GEORGE A SCANGOS | Director | A | — | — |
| 2026-06-11 | Steven Hyman | Director | A | — | — |
| 2026-06-11 | Grace Colon | Director | A | — | — |
| 2026-04-03 | Alfred Sandrock | President and CEO | Sell | — | — |
| 2026-04-03 | Gregory L. Shiferman | SVP and General Counsel | A | — | — |
| 2026-02-26 | Alfred Sandrock | President and CEO | Sell | — | — |
| 2026-02-26 | Robin Swartz | COO & CBO | Sell | — | — |
| 2026-02-26 | Todd Alfred Carter | Chief Scientific Officer | Sell | — | — |
| 2026-02-26 | Nathan D. Jorgensen | Chief Financial Officer | Sell | — | — |
| 2026-02-20 | Todd Alfred Carter | Chief Scientific Officer | Sell | — | — |
| 2026-02-20 | Alfred Sandrock | President and CEO | Sell | — | — |
| 2026-02-20 | Robin Swartz | COO & CBO | Sell | — | — |
| 2026-02-11 | Todd Alfred Carter | Chief Scientific Officer | Sell | — | — |
| 2026-02-11 | Alfred Sandrock | President and CEO | Sell | — | — |
| 2026-02-11 | Robin Swartz | COO & CBO | Sell | — | — |
| 2026-02-10 | Robin Swartz | COO & CBO | A | — | — |
| 2026-02-10 | Alfred Sandrock | President and CEO | A | — | — |
| 2026-02-10 | Nathan D. Jorgensen | Chief Financial Officer | A | — | — |
| 2026-02-10 | Todd Alfred Carter | Chief Scientific Officer | A | — | — |
| 2026-02-10 | Toby Ferguson | Chief Medical Officer | A | — | — |
| 2026-01-08 | Gregory L. Shiferman | SVP and General Counsel | A | — | — |
| 2025-10-07 | Nathan D. Jorgensen | Chief Financial Officer | Sell | — | — |
| 2025-08-20 | Toby Ferguson | Chief Medical Officer | Sell | — | — |
| 2025-06-04 | CATHERINE J MACKEY | Director | A | — | — |
| 2025-06-04 | Jude Onyia | Director | A | — | — |
| 2025-06-04 | Steven Hyman | Director | A | — | — |
| 2025-06-04 | Grace Colon | Director | A | — | — |
| 2025-06-04 | GEORGE A SCANGOS | Director | A | — | — |
| 2025-06-04 | Nancy Vitale | Director | A | — | — |
| 2025-06-04 | GLENN PIERCE | Director | A | — | — |
| 2025-06-04 | Michael J Higgins | Director | A | — | — |
| 2025-06-04 | JAMES A GERAGHTY | Director | A | — | — |
| 2025-04-04 | Alfred Sandrock | President and CEO | Sell | — | — |
| 2025-04-04 | Toby Ferguson | Chief Medical Officer | Sell | — | — |
| 2025-02-24 | Sandell Jacquelyn Fahey | Chief Legal Officer | A | — | — |
| 2025-02-24 | Nathan D. Jorgensen | Chief Financial Officer | A | — | — |
| 2025-02-24 | Toby Ferguson | Chief Medical Officer | A | — | — |
| 2025-02-24 | Alfred Sandrock | President and CEO | MIXED | — | — |
| 2025-02-24 | Todd Alfred Carter | Chief Scientific Officer | MIXED | — | — |
| 2025-02-24 | Robin Swartz | COO & CBO | MIXED | — | — |
| 2025-02-12 | Todd Alfred Carter | Chief Scientific Officer | Sell | — | — |
| 2025-02-12 | Robin Swartz | COO & CBO | Sell | — | — |
| 2025-02-12 | Sandell Jacquelyn Fahey | Chief Legal Officer | Sell | — | — |
| 2025-02-12 | Alfred Sandrock | President & CEO | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 11,061,176 | — |
| — | 10%+ Owner | 8,575,316 | — |
| — | Director | 6,424,205 | — |
| — | 10%+ Owner | 5,778,905 | — |
| — | 10%+ Owner | 4,813,933 | — |
| — | 10%+ Owner | 3,961,507 | — |
| — | — | 2,352,941 | — |
| — | Chief Executive Officer | 872,351 | — |
| — | President and CEO | 472,549 | — |
| — | 10%+ Owner | 470,588 | — |
| — | President & CEO | 322,375 | — |
| — | COO & CBO | 199,738 | — |
| — | Chief Medical Officer | 183,914 | — |
| — | Chief Financial Officer | 175,669 | — |
| — | Chief Scientific Officer | 163,688 | — |
| — | Chief Financial Officer | 151,416 | — |
| — | Chief Scientific Officer | 145,718 | — |
| — | Chief Legal Officer | 123,143 | — |
| — | See remarks | 120,509 | — |
| — | Chief Financial Officer | 109,894 | — |
| — | Senior VP & General Counsel | 102,200 | — |
| — | 10%+ Owner | 86,265 | — |
| — | Director | 76,588 | — |
| — | VP, Finance | 52,458 | — |
| — | SVP and General Counsel | 50,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VYGR quote page; the site-wide leaderboard is on the insider transactions hub.